| Carla Wilhelmina Schnitzlein, DO | |
|
189 Storrs Road, Natchaug Hospital, Mansfield Center, CT 06250-1683 | |
| (860) 456-5906 | |
| Not Available |
| Full Name | Carla Wilhelmina Schnitzlein |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 14 Years |
| Location | 189 Storrs Road, Mansfield Center, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679894679 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 0102203131 (Virginia) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 064598 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Hospital | 2567366016 | 827 |
| Natchaug Hospital, Inc | 5395648737 | 16 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Entity Name | Windham Community Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023191467 PECOS PAC ID: 2961309059 Enrollment ID: O20031217000231 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Entity Name | Natchaug Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295811321 PECOS PAC ID: 5395648737 Enrollment ID: O20040202000008 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Entity Name | The William W Backus Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467517235 PECOS PAC ID: 0749170645 Enrollment ID: O20040316000739 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carla Wilhelmina Schnitzlein, DO 189 Storrs Road, Natchaug Hospital, Mansfield Center, CT 06250-1683 Ph: (860) 456-5906 | Carla Wilhelmina Schnitzlein, DO 189 Storrs Road, Natchaug Hospital, Mansfield Center, CT 06250-1683 Ph: (860) 456-5906 |
News Archive
Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.
Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.
Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.
A study published in Cell Reports shows how next generation genetic sequencing can track mutations in the SARS-CoV-2 virus, which can in effect help with transmission tracing, diagnostic testing accuracy and vaccine effectiveness.
› Verified 5 days ago
Dr. Craig Martin, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 Fax: 860-450-0165 | |
Dr. Vanessa Rose Green, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Deborah A Weidner, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 189 Storrs Rd, Natchaug Hospital, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Paul E. Weigle, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 Fax: 860-423-5922 | |
Gengyun Wen, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 189 Storrs Rd, Natchaug Hospital, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Dr. Sarah Jane De Asis Vargas, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 140 N Frontage Rd, Mansfield Center, CT 06250 Phone: 860-774-2020 | |
Dr. Stanley Paul Dugan, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9 Overlook Dr, Mansfield Center, CT 06250 Phone: 860-456-0257 |